TY - JOUR T1 - Quantifying aerosol and droplet generation during upper and lower gastrointestinal endoscopy: whole procedure and event-based analysis JF - medRxiv DO - 10.1101/2021.04.15.21255544 SP - 2021.04.15.21255544 AU - Frank Phillips AU - Jane Crowley AU - Samantha Warburton AU - George S.D. Gordon AU - Adolfo Parra-Blanco Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255544.abstract N2 - Objective Aerosol generating procedures have become an important healthcare issue due to the COVID-19 pandemic, as the SARS-CoV-2 virus can be transmitted via aerosols. We aimed to characterise aerosol and droplet generation in gastrointestinal endoscopy, where there is little evidence.Design This prospective observational study included patients undergoing routine per-oral gastroscopy (POG, n=36), trans-nasal endoscopy (TNE, n=11) and lower gastrointestinal (LGI) endoscopy (n=48). Particle counters took measurements near the appropriate orifice (two models used, diameter ranges 0.3µm-25µm and 20µm-3000µm). Quantitative analysis was performed by recording specific events and subtracting the background particles.Results POG produced 2.06x the level of background particles (p<0.001), and 2.13x the number of particles compared to TNE. LGI procedures produce significant particle counts (p<0.001), with a rate of 8.8×106/min/m3 compared to 13.0×106/min/m3 for POG. Events significant relative to the noise floor of background particles were: POG-throat spray (112.3x, p<0.01), oesophageal extubation (36.7x, p<0.001), coughing/gagging (30.7x, p<0.01); TNE-nasal spray (32.8x, p<0.01), nasal extubation (25.6x, p<0.01), coughing/gagging (23.3x, p<0.01); LGI-rectal intubation (3.5x, p<0.05), rectal extubation (11.8x, p<0.01), application of abdominal pressure (4.9x, p<0.05). These all produced particle counts larger than or comparable to volitional cough.Conclusions Gastrointestinal endoscopy performed via the mouth, nose or rectum all generates significant quantities of aerosols and droplets. As the infectivity of procedures is not established, we therefore suggest adequate PPE is used for all GI endoscopy where there is a high population prevalence of COVID-19. Avoiding throat and nasal spray would significantly reduce particles generated from UGI procedures.What is already known on this subject?The way we deliver healthcare has dramatically changed since the start of the COVID-19 pandemic. This includes gastrointestinal endoscopy, with precautions in place such as enhanced personal protective equipment, ventilation standards and prioritisation of procedures. Little research has been performed on establishing endoscopy as an aerosol generating procedure (AGP). Two recent studies indicate per-oral gastroscopy is an AGP. However, there is no data on the causative events within procedures, limited particle size analysis, and no data on trans-nasal endoscopy (TNE) or lower gastrointestinal (LGI) endoscopy.What are the new findings?This study greatly expands our knowledge of aerosol and droplet generation during gastrointestinal endoscopy. We show that per-oral gastroscopy (POG), TNE and LGI endoscopy all produce aerosols and droplets. We have quantified this to show that POG produces double the amount of background particles, whilst TNE produces half the particles and LGI a third lower particles than POG per unit time. We use a novel subtraction technique to analyse individual events within endoscopic procedures. This shows that anaesthetic spray is the major contributor for upper gastrointestinal (UGI) endoscopy, followed by coughing/gagging as well as extubation. For LGI endoscopy, the main contributors are rectal extubation, abdominal pressure application and rectal intubation, which produce more particles in the droplet range. All these events are at least comparable to volitional cough, whilst anaesthetic throat spray produces particle counts ten times higher. Furthermore, the presence of a hiatus hernia appears to increase particle generation for UGI endoscopy, whilst high patient discomfort does this for LGI endoscopy. Lastly, we show that particles sizes of some events, such as oral and rectal extubation, are significantly greater than the average particle size of a volitional cough. We also use a spray characteriser to show that particles of up to 300µm are produced in UGI extubation and fundal retroflexion.How might it impact on clinical practice in the foreseeable future?The results in this study give important information for how we deliver endoscopy when there is a threat to the safety of healthcare workers and patients from transmissible infections. It is therefore relevant not only for the current COVID-19 pandemic, but also for other potential respiratory and gastrointestinal pathogens. As the infectivity of procedures is not established, we therefore suggest adequate PPE is used for all GI endoscopy where there is a high population prevalence of COVID-19. We show that for UGI endoscopy, alternatives to local anaesthesia spray would significantly reduce aerosol and droplet generation. The use of TNE would be desirable as it produces less aerosols than POG, but still additional mitigating strategies would be required. For LGI endoscopy, good technique that limits patient discomfort may mitigate aerosol and droplet generation. Further research needs to be done on infectivity of endoscopic procedures and barrier mitigating devices.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors also thank Nottingham University Hospitals NHS Trust for funding the rental of the N60 spray characteriser and rental of a particle counter, and Norgine Pharmaceuticals for sponsoring the purchase of a particle counter. GSDG would like to acknowledge a UKRI Future Leaders Fellowship (MR/T041951/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Wales Research Ethics Committee - IRAS 285595All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData associated with this publication is available at http://dx.doi.org/10.17639/nott.7112 Code used for data analysis in this publication can be found at https://github.com/gsdgordon/aerosols http://dx.doi.org/10.17639/nott.7112 ER -